Clinical Applications of Ultrasound in Cancer Imaging and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 877

Special Issue Editor


E-Mail Website
Guest Editor
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Interests: ultrasound imaging; spectroscopy of cancer therapy responses

Special Issue Information

Dear Colleagues,

Ultrasound is a non-invasive, safe, and widely available imaging modality that has been utilized in the diagnosis and management of many medical conditions. In recent years, it has also emerged as an important tool in the detection and characterization of cancer. Ultrasound provides real-time imaging and is particularly useful for evaluating superficial structures and organs such as the breasts, liver, thyroid and lymph nodes. One of the key advantages of ultrasound is its ability to differentiate between malignant and benign lesions. This is achieved by analyzing the echo pattern and other features of the lesion. In addition, ultrasound is used to guide biopsies and other interventional procedures, such as radiofrequency ablation and cryotherapy, with high precision.

Ultrasound is often used in combination with other imaging modalities such as CT and MRI to provide a comprehensive evaluation of cancer. It is also useful in monitoring the response to treatment and detecting tumor recurrence. Overall, ultrasound has tremendous potential in the clinical management of cancer and continues to evolve with the development of new techniques and technologies.

This Special Issue aims to explore the latest advancements in ultrasound imaging technology for the detection and treatment of various types of cancer.

Prof. Dr. Gregory Jan Czarnota
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ultrasound
  • imaging
  • CT
  • MRI
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 31067 KiB  
Article
Feasibility of Non-Invasive Sentinel Lymph Node Identification in Early-Stage NSCLC Through Ultrasound Guided Intra-Tumoral Injection of 99mTc-Nanocolloid and Iodinated Contrast Agent During Navigation Bronchoscopy
by Desi K. M. ter Woerds, Roel L. J. Verhoeven, Erik H. J. G. Aarntzen and Erik H. F. M. van der Heijden
Cancers 2024, 16(22), 3868; https://doi.org/10.3390/cancers16223868 - 19 Nov 2024
Viewed by 483
Abstract
Background: As the first sentinel lymph nodes (SLN) in lung cancer are most likely to harbor metastasis, their non-invasive identification could have a significant role in future treatments. We investigated the feasibility of adding an SLN procedure to a diagnostic navigation bronchoscopy. [...] Read more.
Background: As the first sentinel lymph nodes (SLN) in lung cancer are most likely to harbor metastasis, their non-invasive identification could have a significant role in future treatments. We investigated the feasibility of adding an SLN procedure to a diagnostic navigation bronchoscopy. Methods: Thirty-one patients were included for injection of 99mTc-nanocolloid and an iodinated contrast agent intra-/peritumorally and assessment of tracer dissipation via SPECT and CBCT imaging. Injections were performed endobronchially using a multi-modal catheter (Pioneer Plus), combining radial ultrasound and an angulated retractable needle to place injections under fluoroscopy and real-time ultrasound. Results: The injection of an imaging tracer was feasible in all cases using the catheter. Ultrasound visualized 29/30 tumors, and tracer injection was performed in 100% of patients. An SLN was subsequently identified in 10 out of 31 cases (32.3%) via SPECT/CT imaging. Iodinated contrast agent injection under CBCT imaging prior to 99mTc nanocolloid injection visualized dissipation pathways and enabled needle relocation for subsequent 99mTc-nanocolloid injection. Conclusions: Performing imaging tracer injections with a multi-modal catheter provided safe and local depot placement immediately following diagnostic navigation bronchoscopy. SPECT/CT imaging using 99mTc-nanocolloid showed inconsistent results for SLN identification. Full article
(This article belongs to the Special Issue Clinical Applications of Ultrasound in Cancer Imaging and Treatment)
Show Figures

Figure 1

Back to TopTop